507 related articles for article (PubMed ID: 29658117)
1. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
2. The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.
Creech AL; Ting YS; Goulding SP; Sauld JFK; Barthelme D; Rooney MS; Addona TA; Abelin JG
Proteomics; 2018 Jun; 18(12):e1700259. PubMed ID: 29314742
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.
Backert L; Kowalewski DJ; Walz S; Schuster H; Berlin C; Neidert MC; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Kanz L; Salih HR; Kohlbacher O; Weisel K; Rammensee HG; Stevanovic S; Walz JS
Oncotarget; 2017 Jul; 8(27):43915-43924. PubMed ID: 28159928
[TBL] [Abstract][Full Text] [Related]
4. Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Abelin JG; Harjanto D; Malloy M; Suri P; Colson T; Goulding SP; Creech AL; Serrano LR; Nasir G; Nasrullah Y; McGann CD; Velez D; Ting YS; Poran A; Rothenberg DA; Chhangawala S; Rubinsteyn A; Hammerbacher J; Gaynor RB; Fritsch EF; Greshock J; Oslund RC; Barthelme D; Addona TA; Arieta CM; Rooney MS
Immunity; 2019 Oct; 51(4):766-779.e17. PubMed ID: 31495665
[TBL] [Abstract][Full Text] [Related]
5. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
6. Immunoinformatics and epitope prediction in the age of genomic medicine.
Backert L; Kohlbacher O
Genome Med; 2015 Nov; 7():119. PubMed ID: 26589500
[TBL] [Abstract][Full Text] [Related]
7. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
8. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
9. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
[TBL] [Abstract][Full Text] [Related]
10. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
11. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
12. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.
Wilhelm M; Zolg DP; Graber M; Gessulat S; Schmidt T; Schnatbaum K; Schwencke-Westphal C; Seifert P; de Andrade Krätzig N; Zerweck J; Knaute T; Bräunlein E; Samaras P; Lautenbacher L; Klaeger S; Wenschuh H; Rad R; Delanghe B; Huhmer A; Carr SA; Clauser KR; Krackhardt AM; Reimer U; Kuster B
Nat Commun; 2021 Jun; 12(1):3346. PubMed ID: 34099720
[TBL] [Abstract][Full Text] [Related]
13. Identification of the Cryptic HLA-I Immunopeptidome.
Erhard F; Dölken L; Schilling B; Schlosser A
Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
[TBL] [Abstract][Full Text] [Related]
14. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
Zhang X; Qi Y; Zhang Q; Liu W
Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
[TBL] [Abstract][Full Text] [Related]
15. Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.
Álvaro-Benito M; Morrison E; Abualrous ET; Kuropka B; Freund C
Front Immunol; 2018; 9():872. PubMed ID: 29774024
[TBL] [Abstract][Full Text] [Related]
16. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
[TBL] [Abstract][Full Text] [Related]
17. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry.
Lorente E; Marcilla M; de la Sota PG; Quijada-Freire A; Mir C; López D
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638844
[TBL] [Abstract][Full Text] [Related]
18. New light on the HLA-DR immunopeptidomic landscape.
Egholm Bruun Jensen E; Reynisson B; Barra C; Nielsen M
J Leukoc Biol; 2024 Apr; 115(5):913-925. PubMed ID: 38214568
[TBL] [Abstract][Full Text] [Related]
19. Improving the prediction of HLA class I-binding peptides using a supertype-based method.
Wang S; Bai Z; Han J; Tian Y; Shang X; Wang L; Li J; Wu Y
J Immunol Methods; 2014 Mar; 405():109-20. PubMed ID: 24508661
[TBL] [Abstract][Full Text] [Related]
20. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]